Development and validation of a clinical prediction model to estimate the risk of critical patients with COVID-19

Wenyu Chen1, Ming Yao2, Lin Hu3

  • 1Department of Respiration, Affiliated Hospital of Jiaxing University/The First Hospital of Jiaxing, Jiaxing, China.

Insights

This study developed a COVID-19 prediction model using clinical features to identify patients at high risk of critical illness. The model, incorporating age and comorbidities, aids early clinical diagnosis and resource allocation.

Area of Science:

  • Medical Informatics
  • Infectious Diseases
  • Clinical Prediction Modeling

Background:

  • The COVID-19 pandemic has severely impacted global healthcare systems.
  • Predicting disease progression is crucial for managing patient outcomes and resource allocation.

Purpose of the Study:

  • To develop and validate a clinical prediction model for estimating the risk of COVID-19 patients progressing to critical illness upon admission.
  • To identify key clinical features associated with severe COVID-19 progression.

Main Methods:

  • Retrospective cohort study of 390 COVID-19 patients admitted between January 16 and March 10, 2020.
  • Utilized Least Absolute Shrinkage and Selection Operator (LASSO) regression to identify significant predictors.
  • Model validation using area under the curve (AUC), specificity, and sensitivity.

Main Results:

  • A prediction model was developed using 6 key variables: age, number of comorbidities, CT severity score, lymphocyte count, aspartate aminotransferase, and albumin.
  • The model achieved an AUC of 0.898 in the training set, with 89.7% specificity and 75.5% sensitivity.
  • The nomogram demonstrated potential utility in assessing the risk of severe and critical illness.

Conclusions:

  • The developed prediction model and nomogram may assist clinicians in identifying COVID-19 patients at high risk of critical illness at the time of admission.
  • This tool can inform clinical decision-making and potentially improve patient management strategies.